We have a twofold strategy:
Internal to MD Anderson
Invest in the best MD Anderson technologies for Phase I trials.
External to MD Anderson
Fund-promising, globally sourced oncology therapies that will work with MD Anderson during Phase I or early Phase II clinical trials.
An elite committee of researchers and clinicians at MD Anderson conducts scientific diligence on all opportunities prior to any investment.
MD Anderson will design and execute clinical trials for Focus Fund investments. Portfolio companies will be able to leverage MD Anderson’s best-in-class facilities and services with the goal of executing clinical trials with maximized potential for success.
We expect to invest in approximately 10 to 12 promising therapies. Up to 20% of committed capital may be designated for special situations, including earlier or future rounds of financing for portfolio companies.
Exclusive arrangement with MD Anderson.
- Specially designated Scientific Committee of leading clinicians and innovators to provide scientific diligence on investments
- Preferential pricing on services and prioritization and dedicated development track within the Phase I unit at MD Anderson
- Right of First Offer on MD Anderson technology
Respected Fund leadership from across the healthcare ecosystem with years of diverse specialist experience.
Staggered capital-infusion strategy provides opportunities for the Fund.
- Structured to provide return of capital early if Fund deems prudent, or flexibility for longer hold period